Immunic (Immunic) GF Score : 41/100 (As of May. 24, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Immunic GF Score?

Immunic has the GF Score of 41, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 8/10
2. Profitability Rank : 2/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 5/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Immunic might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Immunic's GF Score

For the Biotechnology subindustry, Immunic's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunic's GF Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunic's GF Score distribution charts can be found below:

* The bar in red indicates where Immunic's GF Score falls into.

Immunic (NAS:IMUX) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Immunic GF Score Related Terms

Thank you for viewing the detailed overview of Immunic's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunic (Immunic) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunic Inc (NAS:IMUX) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

10VA:Germany

Address

1200 Avenue of the Americas, Suite 200, New York, NY, USA, 10036

Website

https://www.imux.com

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Executives

Glenn Whaley	officer: PAO and Controller	C/O PERNIX THERAPEUTICS HOLDINGS, INC., 10 NORTH PARK PLACE, SUITE 201, MORRISTOWN NJ 07960
Richard Alan Rudick	director	1200 AVENUE OF THE AMERICAS, SUITE 200, NEW YORK NY 10036
Joerg Neermann	director	IMMUNIC AG, AM KLOPFERSPITZ 19, MARTINSRIED 2M 82152
Daniel Vitt	director, officer: CEO, President	IMMUNIC AG, AM KLOPFERSPITZ 19, MARTINSRIED 2M 82152
Monika Maria Toernsen	director	ONE COMMERCE SQUARE, 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Duane Nash	director	C/O VITAL THERAPIES, INC., 15010 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Andreas Muehler	officer: Chief Medical Officer	1200 AVENUE OF THE AMERICAS, SUITE 200, NEW YORK CITY NY 10036
Manfred Groeppel	officer: Chief Operating Officer	IMMUNIC AG, AM KLOPFERSPITZ 19, MARTINSRIED 2M 82152
Barclay A Phillips	director	C/O CANCER VAX CORP, 2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Tamar D Howson	director
Sanjay S Patel	officer: Chief Financial Officer	10 N. PARK PLACE, SUITE 201, MORRISTOWN NJ 07960
Claudio Nessi	10 percent owner	C/O NEOMED, 7 PLACE DU MOLARD, 1204 GENEVA V8 1204
Anne-mari Paster	10 percent owner	C/O OMEGA FUND MANAGEMENT, LLC, 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V Gp, L.p.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Lsp V Cooperatieve U.a.	10 percent owner	JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV